CHF16.84
0.24% today
SIX Swiss Exchange, Apr 02, 05:32 pm CET
ISIN
CH1110760852
Symbol
PPGN
Sector
Industry

PolyPeptide Stock price

CHF16.84
-3.26 16.22% 1M
-11.86 41.32% 6M
-11.56 40.70% YTD
-11.71 41.02% 1Y
-60.06 78.10% 3Y
-45.66 73.06% 5Y
-45.66 73.06% 10Y
SIX Swiss Exchange, Closing price Wed, Apr 02 2025
-0.04 0.24%
ISIN
CH1110760852
Symbol
PPGN
Sector
Industry

Key metrics

Market capitalization CHF556.98m
Enterprise Value CHF581.23m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 168.96
EV/Sales (TTM) EV/Sales 1.81
P/S ratio (TTM) P/S ratio 1.74
P/B ratio (TTM) P/B ratio 1.66
Revenue growth (TTM) Revenue growth 3.15%
Revenue (TTM) Revenue CHF320.27m
EBIT (operating result TTM) EBIT CHF-9.05m
Free Cash Flow (TTM) Free Cash Flow CHF3.44m
EPS (TTM) EPS CHF-0.57
P/E forward 119.78
P/S forward 1.44
EV/Sales forward 1.51
Show more

Is PolyPeptide a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

PolyPeptide Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a PolyPeptide forecast:

3x Buy
50%
2x Hold
33%
1x Sell
17%

Analyst Opinions

6 Analysts have issued a PolyPeptide forecast:

Buy
50%
Hold
33%
Sell
17%

Financial data from PolyPeptide

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
320 320
3% 3%
100%
- Direct Costs 285 285
7% 7%
89%
35 35
762% 762%
11%
- Selling and Administrative Expenses 12 12
7% 7%
4%
- Research and Development Expense 1.04 1.04
27% 27%
0%
22 22
308% 308%
7%
- Depreciation and Amortization 31 31
5% 5%
10%
EBIT (Operating Income) EBIT -9.05 -9.05
77% 77%
-3%
Net Profit -19 -19
63% 63%
-6%

In millions CHF.

Don't miss a Thing! We will send you all news about PolyPeptide directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PolyPeptide Stock News

EQS
3 months ago
Diese Medienmitteilung wurde von der PolyPeptide Group AG erstellt und enthält bestimmte zukunftsgerichtete Aussagen, welche die gegenwärtigen Ansichten des Managements widerspiegeln. Solche Aussagen unterliegen bekannten und unbekannten Risiken, Ungewissheiten und anderen Faktoren, die dazu führ...
AD HOC NEWS
3 months ago
PolyPeptide Group / CH1110760852
More PolyPeptide News

Company Profile

PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1996 and is headquartered in Zug, Switzerland.

Head office Switzerland
CEO Juan-José Gonzalez
Employees 1,362
Founded 1996
Website www.polypeptide.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today